JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: final policy recommendations

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 17, 2021
Language(s):
English
Format:
Text
Subject(s):
Antibodies, Monoclonal
Dermatitis, Atopic
Janus Kinase Inhibitors
United States
Genre(s):
Technical Report
Abstract:
Following its deliberation on the evidence, the Comparative Effectiveness Public Advisory Council engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on the use of oral abrocitinib, baricitinib, and upadacitinib, topical ruxolitinib cream, and subcutaneous tralokinumab. The policy roundtable members included three patient advocates, two clinical experts, two payers, and three representatives from the drug maker(s). The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (11 unnumbered pages))
NLM Unique ID:
9918401084106676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918401084106676